MURRIETA, CA--(Marketwire - June 27, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today issued the June 2008 edition of its investor newsletter, which reviews the current status of the validation study for Zonda Incorporated’s rapid point of care test for chlamydia and the anticipate acquisition of an additional rapid diagnostic test for the medical market.
